© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
August 1st 2018
Investigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.